Healthcare tech company Privia Health Group (NASDAQ: PRVA) will be reporting earnings this Thursday before market hours. Here’s what to look for.

Privia Health beat analysts’ revenue expectations last quarter, reporting revenues of $632.6 million, up 21.4% year on year. It was a satisfactory quarter for the company, with a significant miss of analysts’ EPS estimates.

Is Privia Health a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Privia Health’s revenue to grow 5.3% year on year, slowing from the 32.5% increase it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Privia Health has a history of exceeding Wall Street’s expectations.

Looking at Privia Health’s peers in the healthcare technology segment, only Omnicell has reported results so far. It exceeded analysts’ revenue estimates and delivered flat year-on-year revenue. The stock traded up 1.9% on the results.

There has been positive sentiment among investors in the healthcare technology segment, with share prices up 2.8% on average over the last month. Privia Health is up 5% during the same time and is heading into earnings with an average analyst price target of $31.47 (compared to the current share price of $21.47).

WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.

This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.